GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.
Giulia Carvalhal, Maria Meritxell Roca Mora, Gonzalo Alberto Peralta-Jiménez et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis of randomized controlled trials evaluated the efficacy and safety of GLP-1 receptor agonists in adults with moderate-to-severe obstructive sleep apnea (OSA). The analysis included 1,069 participants and found that these therapies significantly reduced the apnea-hypopnea index (AHI) by -9.99 events/hour and body weight by -9.68 kg compared to control, with p-values < 0.01.
Key findings
- GLP-1 receptor agonists reduced AHI by -9.99 events/hour compared to control.
- Body weight decreased by -9.68 kg with GLP-1 receptor agonist therapy.
- Systolic blood pressure decreased by -4.77 mmHg and diastolic by -1.41 mmHg.
- No significant increase in adverse events was observed with GLP-1 receptor agonists.
Why it matters
The findings suggest that GLP-1 receptor agonists may be beneficial in managing OSA, particularly in overweight and obese patients, by addressing both weight and apnea severity. This could enhance overall treatment strategies for OSA.
What to keep in mind
Substantial heterogeneity among studies limits the interpretation of the pooled effect magnitude.